Zilenta Tablet contains Teneligliptin 20mg, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Teneligliptin enhances the incretin system by inhibiting the DPP-4 enzyme, thereby increasing the levels of active incretin hormones such as GLP-1 and GIP. This mechanism promotes glucose-dependent insulin secretion and suppresses glucagon release, resulting in improved glycemic control without causing significant hypoglycemia. Zilenta is prescribed as an adjunct to diet and exercise to improve glycemic parameters in adult patients inadequately controlled by lifestyle modification alone or in combination with other antidiabetic agents. The 20mg dosage offers effective once-daily administration, enhancing patient compliance. Clinical studies have demonstrated that Teneligliptin is well-tolerated with a favorable safety profile, exhibiting minimal adverse effects and no significant risk of weight gain. It may be used as monotherapy or in combination with metformin, sulfonylureas, or insulin. Caution is advised in patients with renal or hepatic impairment, and dosage adjustments may be necessary. Regular monitoring of blood glucose and HbA1c levels is recommended to assess therapeutic efficacy and guide treatment adjustments. Zilenta Tablet represents a valuable option in the comprehensive management of type 2 diabetes.